A once-daily eye drop that temporarily corrects end-of-life vision loss, or presbyopia, has been successful in an advanced clinical trial, drugmaker Allergan has announced.
Presbyopia is a common and progressive eye condition. It reduces the eye’s ability to focus on nearby objects and affects the majority of adults over the age of 50. Allergan’s experimental eye drops, pilocarpine (AGN-190584), contracts the pupil to an optimal pupil size, improving near vision without affecting distance vision, according to the company.
The trial participants were given a 1.25% formulation of the drug in both eyes, once daily, for 30 days. Compared to placebo, they reported significant improvements in near vision, in low light conditions and without losing distance vision, Allergan reported during a presentation last week at the Association for Research in Vision and Ophthalmology (ARVO) 2021.
The effects are visible as early as 15 minutes after applying the drop and last for about six hours, the company said.
Investigators measured better visual reading performance and better satisfaction. Participants reported less need for coping mechanisms, such as squinting to read, increasing the font size when reading, holding reading materials away from the face, and relying on others for help with activities related to near vision.
Allergan applied for authorization to market pilocarpine eye drops (AGN-190584) in February. He expects a response from the Food and Drug Administration by the end of the year, according to Michael R. Robinson, MD, vice president, head of global therapeutics, eye care, AbbVie, the parent company of Allergan.
If approved, it should be the first and only eye drops approved by the FDA to treat presbyopia and improve blurry near vision, Robinson said.
The drug “may be a great first-line option for people who currently do not have a solution and an alternative or complementary choice for those already using reading glasses and contact lenses who want more flexibility and convenience. “, did he declare.